Cowen lowered shares of PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) from an outperform rating to a market perform rating in a report published on Monday morning, The Fly reports.

Several other equities analysts have also issued reports on PHAS. Stifel Nicolaus lowered PhaseBio Pharmaceuticals from a buy rating to a hold rating and cut their target price for the company from $15.00 to $1.00 in a research note on Wednesday, September 28th. Needham & Company LLC lowered PhaseBio Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, September 28th. William Blair lowered PhaseBio Pharmaceuticals from an outperform rating to a market perform rating in a research note on Wednesday, September 28th. Finally, Cowen lowered PhaseBio Pharmaceuticals to a market perform rating in a research note on Monday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, PhaseBio Pharmaceuticals currently has an average rating of Hold and a consensus price target of $4.50.

PhaseBio Pharmaceuticals Trading Down 28.9 %

Shares of PhaseBio Pharmaceuticals stock opened at $0.14 on Monday. The firm has a market cap of $7.02 million, a P/E ratio of -0.07 and a beta of 2.87. PhaseBio Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $4.08. The stock's fifty day moving average price is $0.73 and its 200-day moving average price is $0.89.

Institutional Investors Weigh In On PhaseBio Pharmaceuticals

Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth about $41,000. Blair William & Co. IL lifted its holdings in shares of PhaseBio Pharmaceuticals by 56.0% during the first quarter. Blair William & Co. IL now owns 35,696 shares of the company's stock worth $47,000 after purchasing an additional 12,810 shares during the period. Prudential Financial Inc. acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter worth about $26,000. Renaissance Technologies LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth about $118,000. Finally, Jane Street Group LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter worth about $68,000. Hedge funds and other institutional investors own 49.02% of the company's stock.

PhaseBio Pharmaceuticals Company Profile

(Get Rating)

PhaseBio Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension.

Featured Stories

• Get a free copy of the StockNews.com research report on PhaseBio Pharmaceuticals (PHAS)
• Is Lithium Stock Albemarle A Buy Before Next Week's Q3 Report?
• Gassed Up: Can Cheniere Energy Keep Climbing?
• Can American Airlines Stock Maintain Altitude?
• New Name SLB's Legacy Business is Behind its Strong Results
• Insiders And Institutions Put A Bottom In Dave & Buster's

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.